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(57) ABSTRACT 
An aqueous composition comprises an amphiphilic block 
copolymer, having a hydrophilic block comprising pendant 
ZWitterionic groups and a hydrophobic block, and a biologi 
cally active compound associated With the polymer. The 
polymer is preferably in the form of micelles, and preferably 
the biological active is a hydrophobic drug, for instance 
having a calculated or experimentally determined logP of at 
least 1.0, Where P is the octanol:Water partition coefficient. 
The hydrophilic block is preferably formed from acrylic 
monomer including phosphoryicholine groups. The hydro 
phobic group is suitably formed from monomer Which has 
groups Which can be ionised at useful pH’s, especially 
tertiary amine groups. Micelles may be formed by dissolv 
ing the block copolymer in aqueous solvent at a pH at Which 
the amine groups are protonated then raising the pH to a 
value at Which the amine groups are substantially deproto 
nated, Whereupon micelles spontaneously form. The pre 
formed micelles are then contacted With active, under con 
ditions such that solubilisation of the active occurs. The 
active may be a Water-insoluble drug, for instance for 
tumour treatment. 
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DRUG CARRIERS COMPRISING AMPHIPHILIC 
BLOCK COPOLYMERS 
[0001] The present invention relates to block copolymers 
for micellar delivery of drugs. It is of particular value for 
delivery of hydrophobic drugs. 
[0002] Micelle based drug delivery systems have been 
developed Which are based on amphiphilic copolymers. 
Such copolymers should have a hydrophobic moiety and a 
hydrophilic moiety. In a micelle, the hydrophobic moieties 
aggregate to form a core, With the hydrophilic moieties 
being revealed at the surface of the micelle Where they 
associate With Water. The micelles can solubilise poorly 
Water-soluble drugs in their inner core. Their small siZe 
renders them suitable for systemic delivery of drugs. The 
core-shell structure provides some protection for the drug in 
the core during transport to a target cell. 
[0003] Although random copolymers may be used, in 
Which some of the monomers have hydrophobic pendant 
groups, most Work has focussed on block copolymers. AB 
diblock copolymers and ABA triblock copolymers, A being 
the hydrophilic block and B being the hydrophobic block 
have been investigated. In most of the block copolymers 
tested to date, the hydrophilic blocks have been provided by 
polyethylene oXide moieties. The hydrophobic block may be 
a polypropylene oXide block, a hydrophobic polypeptide 
(such as poly([3-benZyl-L-aspartate)), a polyester (poly(DL 
lactic acid)) or poly(e-caprolactone). Polystyrene and poly 
(methylmethacrylate) have also been investigated as con 
stituents of the core. 
[0004] Alakhov et al in Biomedical Polymers and Polymer 
Therapeutics, 2001, eds Chiellini et al KluWer Academic/ 
Plenum publishers, NeW York, 121 to 137, describe the use 
of polyethylene oxide-polypropylene oXide block copoly 
mers to deliver doXorubicin. Such compounds are commer 
cially available With loW polydispersity (of molecular 
Weight) under the trade name Pluronic and PoloXamer (trade 
marks). They investigate the effect of the average molecular 
Weight and the hydrophilic/lipophilic balance (HLB) of the 
block copolymer upon cytotoXicity against a panel of cell 
lines. 
[0005] Jones et al in Eur. J. Pharm. Biopharm. 48(1999) 
101 to 111 revieW the disclosures of various block copoly 
mers as colloidal drug carriers, and explains various Ways in 
Which micelles are formed With hydrophobic drug in the 
core. 
[0006] Inoue et al in J. Cont. Rel. 51 (1998) 221 to 229 
describe an AB block copolymer having amphiphilic prop 
erties, in Which one block is formed of methyl methacrylate 
(the hydrophobic core) and the other block is formed of 
acrylic acid units. Polymerisation is conducted by initially 
forming an oligomer of methylmethacrylate units, and using 
this as the initiator for polymerising a block of acrylic acid. 
The average molecular Weight of the hydrophobic block Was 
said to be 4300, although the molecular Weight of the block 
copolymer Was not stated. The physical form of the drug 
delivery system appeared to involve non-micellar structures, 
termed “unimers”. 
[0007] In our earlier applications No WO-A-0228929, not 
pulbished at the priority date hereof We described the 
polymerisation of ZWitterionic monomers by atom transfer 
radical polymerisation techniques, some of the polymers 
Oct. 6, 2005 
Were block copolymers A general suggestion Was made that 
the polymers may have utility in delivery of drugs. 
[0008] According to the present invention there is pro 
vided an aqueous composition comprising an amphiphilic 
block copolymer having a hydrophilic block and a hydro 
phobic block, dispersed in the solution, and a biologically 
active compound associated With the polymer, characterised 
in that the hydrophilic block has pendant ZWitterionic 
groups. 
[0009] The term “associated With” in the present invention 
means that the biologically active molecule has some asso 
ciation With the polymer such that its solubility, bioavail 
ability, immunogenicity, or toXicity, is affected by the inter 
action With the polymer. Although the association is 
normally by Way of the presence of micelles in Which a 
biologically active compound is present in the core, it may 
involve other types of interaction, for instance the “unimer” 
type solutes described by Inoue et al (op. cit). It may involve 
covalent conjugation, but generally involves noncovalent 
interactions, such as electrostatic, or preferably hydrophobic 
interactions. 
[0010] Although the active may be a Water-soluble drug, 
preferably it is relatively Water-insoluble, generally soluble 
in an organic solvent. Generally the active has a solubility 
such that it has a partition coefficient (log P) betWeen octanol 
and Water of at least 1.0, preferably at least 1.5, more 
preferably at least 2.0. The active Will, in the presence of 
micelles of the amphiphilic block copolymer used in the 
invention, be preferentially partitioned into the hydrophobic 
core of micelles, or otherWise associated With the hydro 
phobic block. Examples of suitable drugs are given beloW. 
[0011] Although the hydrophilic block may be based on 
condensation polymers, such as polyesters, polyamides, 
polyanhydrides, polyurethanes, polyethers, polyimines, 
polypeptides, polyureas, polyacetals, polysaccharides or 
polysiloXanes, preferably the hydrophilic block is based on 
a radical polymerised addition polymer of ethylenically 
unsaturated monomers. Generally the monomers from 
Which the block is formed themselves have ZWitterionic 
pendant groups Which remain unchanged in the polymeri 
sation process. It may alternatively be possible to derivatise 
a functional pendant group of a monomer to render it 
ZWitterionic after polymerisation. 
[0012] Suitable ethylenically unsaturated ZWitterionic 
monomers have the general formula 
YBX I 
[0013] in Which Y is an ethylenically unsaturated group 
selected from H2C=CR—CO-A-, H2C=CR—C6H4-A1-, 
H2C=CR—CH2A2, R2O—CO—CR=CR—CO—O, 
RCH=CH—CO—O—, RCH=C(COOR2)CH2—CO—O, 
HR 0 R O 


















